Circulating microemboli in patients with myeloproliferative disorders

Area of Science:

• Hematology
• Neurology
• Vascular Medicine

Background:

• Myeloproliferative disorders (MPD) significantly increase the risk of thrombembolic events.
• Transcranial Doppler (TCD) is used to detect microemboli, but its prognostic value in MPD is not fully understood.

Purpose of the Study:

• To evaluate the prognostic significance of TCD-detected microemboli for clinical events in MPD patients.
• To correlate TCD findings with blood cell counts and platelet flow cytometry to understand microemboli composition.

Main Methods:

• A cohort of 42 MPD patients underwent a single TCD microemboli detection session.
• Prospective follow-up assessed thrombembolic events over approximately 30 months.
• Complete blood counts and platelet flow cytometry were performed concurrently.

Main Results:

• Microembolic signals (MES) were detected in 35.7% of patients but did not correlate with MPD type, blood counts, or thrombembolic events (21.4%).
• No significant differences in platelet activation markers were observed between MES-positive and negative groups.
• A trend towards higher platelet-neutrophil conjugates was noted in MES-positive patients (P=0.09).

Conclusions:

• Single-occasion TCD microemboli detection offers limited prognostic value in MPD.
• MES in MPD do not correlate with disease type or blood cell counts.
• Flow cytometry suggests MES may comprise platelet-neutrophil aggregates in MPD.